Loading...
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
BACKGROUND: Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group tr...
Na minha lista:
| Udgivet i: | N Engl J Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5881572/ https://ncbi.nlm.nih.gov/pubmed/28249141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1609783 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|